Impact of Covid-19 Outbreak on Global Ventilator-Associated Pneumonia (VAP) Market
The COVID-19 epidemic has been straining healthcare workflow across the globe. The outbreak has forced various industries to shut its doors, including many healthcare subdomains temporarily. Parallel to this, it has also had a positive impact and increasing demand for various medical market segments, including intensive care unit devices (beds, ventilators, etc.) and personal healthcare protection equipment, among others. A medical ventilator is one of the major devices that is used for the treatment of COVID-19. There has been a tremendous increasing demand for medical ventilators, forcing various manufacturers to boost their production by 30% to 50%. Various major players are pushing themselves for manufacturing and delivering as many possible ventilators across the world. The increasing usage of ventilators in healthcare facilities is increasing the chances of patients infected with ventilator-associated pneumonia.
Regional impact of COVID-19 pneumonia
In China, many hospitals have estimated that the incidences of pneumonia increase the death rate in COVID-19 patients. In February 2020, a research study conducted in Wuhan Pulmonary Hospital estimated about 76% were diagnosed with COVID-19 pneumonia. COVID-19-induced pneumonia requires medicines that cure pneumonia symptoms.
The US is one of the major countries that has been impacted by COVID-19. There is a huge need for medical ventilators across the country. According to Wall Streets, it is expected that the US is purchasing more than USD 2.5 billion in ventilators for COVID-19 patients. This increasing use of ventilators may lead to chances of ventilator-associated pneumonia in this region.
The number of infected in India is growing. According to a research study published by the Indian Council of Medical Research (ICMR), estimated that about 40% of total COVID-19 patients suffer from symptoms similar to pneumonia. This large number of COVID-19 cases is expected to boost the growth of the pneumonia market in India.
Companies taking opportunity over the covid-19 situation
Hoffmann-La Roche AG
On 28 April 2020, the company announced plans to initiate a phase III clinical trial of canakinumab for patients suffering from COVID-19 pneumonia. This initiative is likely to help the company gain the maximum share in the market.
Merck & Co., Inc.
In June 2019, Merck & Co., Inc. received the US Food and Drug Administration (FDA) approvals for Zerbaxa for treating hospital-acquired and ventilator-associated bacterial pneumonia. As many COVID-19 patients suffer from pneumonia, this drug could help patients to relieve their symptoms of pneumonia.